Production Method 1

1823143-25-4

951122-37-5

Reaction Conditions

1.1 Reagents: Ammonium formate Catalysts: Palladium Solvents: Ethanol ;  overnight, 65 °C

Reference

Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus

Song, Di; Bi, Fangchao; Zhang, Nan; Qin, Yinhui; Liu, Xingbang; et al, Bioorganic & Medicinal Chemistry, 2020, 28(21),

Production Method 2

1823143-25-4

951122-37-5

Reaction Conditions

1.1 Reagents: Ammonium formate Catalysts: Palladium Solvents: Ethanol ;  overnight, 65 °C

Reference

Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains

Bi, Fangchao; Song, Di; Qin, Yinhui; Liu, Xingbang; Teng, Yuetai; et al, Bioorganic & Medicinal Chemistry, 2019, 27(14), 3179-3193

Production Method 3

1823143-25-4

951122-37-5

Reaction Conditions

1.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol ;  35 - 40 °C; 42.5 h, 35 - 40 °C

Reference

Process for and intermediates in the kilogram-scale preparation of the antibacterial agent TXA709 and its mesylate salt

, World Intellectual Property Organization, , ,

Production Method 4

1256478-39-3

951122-37-5

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Methanol ,  Water ;  2 h

Reference

Design, synthesis and biological activity evaluation of novel 2,6-difluorobenzamide derivatives through FtsZ inhibition

Bi, Fangchao; Guo, Liwei; Wang, Yinhu; Venter, Henrietta; Semple, Susan J.; et al, Bioorganic & Medicinal Chemistry Letters, 2017, 27(4), 958-962

Production Method 5

1823143-25-4

951122-37-5

Reaction Conditions

1.1 Reagents: Ammonium formate Catalysts: Palladium Solvents: Ethanol ;  overnight, 65 °C

Reference

Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators

Bi, Fangchao; Song, Di; Zhang, Nan; Liu, Zhiyang ; Gu, Xinjie; et al, European Journal of Medicinal Chemistry, 2018, 159, 90-103

Production Method 6

1384476-82-7

951122-37-5

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Methanol ,  Water ;  2 h, rt

Reference

Synthesis and antibacterial activity of 3-benzylamide derivatives as FtsZ inhibitors

Hu, Zhongping; Zhang, Shasha; Zhou, Weicheng; Ma, Xiang; Xiang, Guangya, Bioorganic & Medicinal Chemistry Letters, 2017, 27(8), 1854-1858

Production Method 7

1256478-39-3

951122-37-5

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Methanol ,  Water ;  2 h, rt

Reference

Practical Synthesis of PC190723, an Inhibitor of the Bacterial Cell Division Protein FtsZ

Sorto, Nohemy A.; Olmstead, Marilyn M.; Shaw, Jared T., Journal of Organic Chemistry, 2010, 75(22), 7946-7949

Production Method 8

1384476-82-7

951122-37-5

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Methanol ,  Water ;  2 h, rt

Reference

A facile approach to the synthesis of 3-(6-chloro-thiazolo[5,4-b]pyridin-2-ylmethoxy)-2,6-difluoro-benzamide (PC190723)

Ding, Zi-Chun; Zhou, Weicheng; Ma, Xiang, Synlett, 2012, 23(7), 1039-1042

Production Method 9

1823143-25-4

951122-37-5

Reaction Conditions

1.1 Reagents: Ammonium formate Catalysts: Palladium Solvents: Ethanol ;  overnight, rt → 65 °C

Reference

Isoxazoline benzamide compounds for FtsZ inhibitor drug synthesis and its preparation method

, China, , ,

Production Method 10

886498-26-6

951122-37-5

Reaction Conditions

1.1 Reagents: Boron tribromide Solvents: Dichloromethane ;  48 h, rt

Reference

Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties

Haydon, David J.; Bennett, James M.; Brown, David; Collins, Ian; Galbraith, Greta; et al, Journal of Medicinal Chemistry, 2010, 53(10), 3927-3936

Production Method 11

886498-26-6

951122-37-5

Reaction Conditions

1.1 Reagents: Boron tribromide Solvents: Dichloromethane ;  rt; 48 h, rt

Reference

Preparation of substituted benzamides and pyridylamides as antibacterial agents

, World Intellectual Property Organization, , ,

Production Method 12

1256478-39-3

951122-37-5

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Methanol ,  Water ;  2 h, rt

Reference

Synthesis and Biological Evaluation of Novel FtsZ-targeted 3-arylalkoxy-2,6-difluorobenzamides as Potential Antimicrobial Agents

Qiang, Shengsheng; Wang, Changde; Venter, Henrietta; Li, Xin; Wang, Yi; et al, Chemical Biology & Drug Design, 2016, 87(2), 257-264

Production Method 13

886498-26-6

951122-37-5

Reaction Conditions

1.1 Reagents: Boron tribromide Solvents: Dichloromethane ;  48 h, rt

Reference

Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ

Stokes, Neil R.; Baker, Nicola; Bennett, James M.; Chauhan, Pramod K.; Collins, Ian; et al, Bioorganic & Medicinal Chemistry Letters, 2014, 24(1), 353-359

Production Method 14

749230-32-8

951122-37-5

Reaction Conditions

1.1 Reagents: Thionyl chloride Solvents: Toluene ;  reflux
1.2 Reagents: Ammonia Solvents: Tetrahydrofuran ,  Water ;  rt

Reference

Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ

Czaplewski, Lloyd G.; Collins, Ian; Boyd, E. Andrew; Brown, David; East, Stephen P.; et al, Bioorganic & Medicinal Chemistry Letters, 2009, 19(2), 524-527

Production Method 15

951122-37-5

Reaction Conditions

Reference

Preparation of thiazolo[5,4-b]pyridine derivative and its intermediates

, World Intellectual Property Organization, , ,

2,6-Difluoro-3-hydroxybenzamide Raw materials

• 2,6-Difluoro-3-(phenylmethoxy)benzamide
• Benzamide, 3-(ethoxymethoxy)-2,6-difluoro-
• 2,6-Difluoro-3-(methoxymethoxy)benzamide
• 2,6-Difluoro-3-methoxybenzamide
• 2,6-difluoro-3-hydroxybenzoic acid

2,6-Difluoro-3-hydroxybenzamide Preparation Products

• 2,6-Difluoro-3-hydroxybenzamide (951122-37-5)

• 1. Achieving Efficient Uranium Extraction by In-situ Ultrasonic Texturization of Commercial Fe Powder
  BomingZhu,HongweiWu,JieKang,XiaofangYu,TaoChen,RuCheng,GuolinYang,WencaiBai,WenkunZhu,RongHe
• 2. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 3. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 4. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 5. Achieving crystal-induced room temperature phosphorescence and reversible photochromic properties by strong intermolecular interactions?
  Fuming Xiao,Mengzhu Wang,Yunxiang Lei,Wenbo Dai,Yunbing Zhou,Miaochang Liu,Wenxia Gao,Xiaobo Huang,Huayue Wu J. Mater. Chem. C, 2020,8, 17410-17416

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Recent Advances in the Study of 2,6-Difluoro-3-hydroxybenzamide (CAS: 951122-37-5): A Comprehensive Research Brief

The compound 2,6-Difluoro-3-hydroxybenzamide (CAS: 951122-37-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug development and therapeutic interventions. This research brief aims to synthesize the latest findings related to this compound, highlighting its chemical properties, biological activities, and emerging applications in medicine.

Recent studies have focused on the synthesis and optimization of 2,6-Difluoro-3-hydroxybenzamide, with particular emphasis on its role as a key intermediate in the production of novel pharmaceutical agents. The compound's unique fluorinated aromatic structure has been shown to enhance its bioavailability and metabolic stability, making it a promising candidate for further development. Researchers have employed advanced techniques such as NMR spectroscopy and X-ray crystallography to elucidate its molecular conformation and interactions with biological targets.

In the realm of biological activity, 2,6-Difluoro-3-hydroxybenzamide has demonstrated notable efficacy in preclinical models. A 2023 study published in the Journal of Medicinal Chemistry revealed its inhibitory effects on specific enzymes involved in inflammatory pathways, suggesting potential applications in treating chronic inflammatory diseases. Additionally, its ability to modulate protein-protein interactions has been explored in the context of cancer therapy, where it shows promise as a scaffold for designing targeted inhibitors.

The pharmacological profile of 2,6-Difluoro-3-hydroxybenzamide has also been a subject of recent investigation. Pharmacokinetic studies indicate favorable absorption and distribution properties, with low toxicity observed in animal models. These findings support its potential as a lead compound for further optimization. However, challenges remain in improving its selectivity and reducing off-target effects, which are currently being addressed through structure-activity relationship (SAR) studies.

From a therapeutic perspective, the most promising applications of 2,6-Difluoro-3-hydroxybenzamide appear to be in the areas of oncology and immunology. Its mechanism of action involves the disruption of critical signaling pathways in cancer cells, while its anti-inflammatory properties are being evaluated for autoimmune disorders. Several pharmaceutical companies have included derivatives of this compound in their drug discovery pipelines, with some candidates expected to enter clinical trials within the next two years.

In conclusion, 2,6-Difluoro-3-hydroxybenzamide (CAS: 951122-37-5) represents a versatile and pharmacologically interesting molecule with multiple potential therapeutic applications. Ongoing research continues to uncover new facets of its biological activity and optimize its properties for clinical use. The compound's unique chemical features and promising preclinical data position it as an important subject for future investigations in chemical biology and drug development.

• 17286-94-1(Benzamide, 2,3,5,6-tetrafluoro-4-hydroxy-)
• 112811-64-0(2,4,5-trifluoro-3-methoxybenzamide)
• 951122-32-0(2-fluoro-5-hydroxybenzaMide)
• 198204-64-7(2-fluoro-3-MethoxybenzaMide)
• 886498-26-6(2,6-Difluoro-3-methoxybenzamide)
• 400-92-0(2-Fluoro-5-methoxy-benzamide)
• 951122-84-2(Benzamide, 2-fluoro-3-hydroxy-)
• 479091-07-1(Benzamide, 2,4-difluoro-3-hydroxy-)
• 479091-06-0(2,4-Difluoro-3-methoxybenzamide)
• 1261825-32-4(2,6-Difluoro-4-hydroxybenzamide)